Measurements of human breast cancer using magnetic resonance spectroscopy: A review of clinical measurements and a report of localized 31P measurements of response to treatment

NMR in Biomedicine

Volumn 11, Issue 7, 1998, Pages 314-340

  Leach, M O ^a   Verrill, M ^a   Glaholm, J ^a,b   Smith, T A D ^a   Collins, D J ^a   Payne, G S ^a   Sharp, J C ^a,c   Ronen, S M ^a   McCready, V R ^a   Powles, T J ^a   Smith, I E ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

31p MRS; Breast rumours; Phospholipid metabolism

Indexed keywords

ANTIESTROGEN; CYCLOPHOSPHAMIDE; ESTROGEN; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PHOSPHODIESTER; PHOSPHOETHANOLAMINE; PHOSPHOMONOESTER; TAMOXIFEN; UNCLASSIFIED DRUG;

BREAST CANCER; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHOLIPID METABOLISM; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; PHOSPHOLIPIDS; PHOSPHORUS RADIOISOTOPES; RADIOTHERAPY;

ANIMALIA;

EID: 7844235474     PISSN: 09523480     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1492(1998110)11:7<314::AID-NBM522>3.0.CO;2-Z     Document Type: Review

References (106)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347, 1713-1727 (1996).
2. Bergkvist L., Adami H., Persson I., Hoover R. and Schaker C. The risk of breast cancer after estrogen and estrogen-progestin replacement New England J. Med. 321, 293-297 (1989).
3. Buell P. Changing incidence of breast cancer in Japanese-American women. J. Natl Cancer Inst. 51, 1479-1483 (1973).
4. Gentili C., Sanfilippo O. and Silvestrini R. Cell proliferation and its relationship to clinical features and relapse in breast cancers. Cancer 48, 974-979 (1981).
5. Hermanek P. and Sobin L. H. UICC TNM Classification of malignant tumours. Springer, Berlin (1996).
6. Cancer Guidance sub-group of the Clinical Outcomes Group. Guidance to Purchasers - Improving Outcomes in Breast Cancer - The Research Evidence. Department of Health, London (1996).
7. Cancer Guidance sub-group of the Clinical Outcomes Group. Guidance for Purchasers - Improving Outcomes in Breast Cancer - The Manual. Department of Health, London (1996).
8. Smith I. E., Jones A. L., O'Brien M. E. R., McKinna J. A., Sacks N. and Baum M. Erratum: primary medical (neo-adjuvant) chemotherapy for operable breast cancer (European Journal of Cancer (1993), no. 4, pp. 592-595). Eur. J. Cancer Part A Gen Top 29, 1796-1799 (1993).
9. Hickish T. F., Powles T. J., O'Brien M. E., Ashley S. E., Tidy V. A., Nash A. G., Cosgrove D. and Ford H. T. A randomized trial of adjuvant vs neoadjuvant chemo-endocrine therapy for the treatment of operable primary breast cancer (abstract). Br. J. Cancer 69(Suppl 21), 21 (1994).
10. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 5, 303-324 (1992).
11. 31P nuclear magnetic resonance spectroscopy: a review. Cancer Res. 49, 4075-4085 (1989).
12. de Certaines J., Larsen V. A., Podo F., Carpinelli G., Briot O. and Henriksen O. In vivo 31P MRS of experimental tumours. NMR Biomed. 6, 345-365 (1993).
13. Leach M. O. Magnetic resonance spectroscopy applied to clinical oncology. Health Care Tech. 2, 235-246 (1994).
14. Leach M. O., Le Moyec L. and Podo F. MRS of tumours: basic principles. In Magnetic Resonance Spectroscopy in Biology and Medicine, ed. by J. D. de Certaines, W. M. M. J. Bovee and F. Podo, pp. 295-344. Pergamon, Oxford, (1992).
15. Proceedings of the Special Symposium on "Lipid Metabolism and Function in Cancer. Significance of Magnetic resonance Spectroscopy (MRS) Measurements in Relation to Biochemical Processes and Cellular Control", Anticancer Res. 16 (3B) (1996).
16. Payne G. S., Dowsett M. and Leach M. O. Hormone-dependent metabolic changes in the normal breast monitored non invasively by 31P magnetic resonance (MR) spectroscopy. Breast 3, 20-23 (1994).
17. Twelves C. J., Porter D. A., Lowry M., Dobbs N. A., Graves P. E., Smith M. A., Rubens R. D. and Richards M. A Phosphorus-31 metabolism of post-menopausal breast cancer studied in vivo by magnetic resonance spectroscopy. Br. J. Cancer 69, 1151-1156 (1994).
18. Chu D. Z. Yamanashi W. S., Frazer J., Hazlewood C. F., Gallager H. S., Boddie A. W. and Martin R. G. Proton NMR of human breast tumors: correlation with clinical prognostic parameters. J. Surg. Oncol. 36, 1-4 (1987).
19. Bradamante S., Barchiesi E., Pilotti S. and Borasi G. High-resolution 1H NMR spectroscopy in the diagnosis of breast cancer. Magn. Reson. Med. 8, 440-449 (1988).
20. Smith T. A., Bush C., Jameson C., Titley J. C., Leach M. O., Wilman D. E. and McCready V. R. Phospholipid metabolites, prognosis and proliferation in human breast carcinoma. NMR. Biomed. 6, 318-323 (1993).
21. Kalra R., Wade K. E., Hands L., Styles P., Camplejohn R., Greenall M., Adams G. E., Harris A. L. and Radda G. K. Phosphomonoester is associated with proliferation in human breast cancer: a 31P MRS study. Br. J. Cancer 67, 1145-1153 (1993).
22. Sakai K., Okuyama H., Yura J., Takeyama H., Shinagawa N., Tsuruga N., Kato K., Kawase K. and Tsujimura T. et al. Composition and turnover of phospholipids and neutral lipids in human breast cancerand reference tissues. Carcinogenesis 13, 579-584 (1992).
23. Williams C. M. and Maunder K. Fatty acid compositions of inositol and choline phospholipids of breast tumours andnormal breast tissue. Eur. J. Clin. Nutr. 47, 260-267 (1993).
24. Bougnoux P., Chajes V., Lanson M., Hacene K., Body G., Couet C. and Le Floch O. Prognostic significance of tumor phosphatidylcholine stearic acid level in breast carcinoma. Breast Cancer Res. Treat. 20, 185-194 (1992).
25. Victor T A., Bergman A. and Knop R. H. Detecting fatty acids of dietary origin in normal and cancerous human breast tissue by 13C nuclear magnetic resonance spectroscopy. Br. J. Cancer 68, 336-341 (1993).
26. Degani H., Horowitz A. and Itzchak Y. Breast tumors: evaluation with P-31 MR spectroscopy. Radiology 161, 53-55 (1986).
27. Barzilai A., Horowitz A., Geier A. and Degani H. Phosphate metabolites and steroid hormone receptors of benign and malignant breast tumors. A nuclear magnetic resonance study. Cancer 67, 2919-2925 (1991).
28. Merchant T. E., Gierke L. W., Meneses P. and Glonek T. 31P magnetic resonance spectroscopic profiles of neoplastic human breast tissues. Cancer Res 48, 5112-5118 (1988).
29. Sijens P. E., Wijrdeman H. K., Moerland M. A. Bakker C. J., Vermeulen J. W. and Luyten P. R. Human breast cancer in vivo: H-1 and P-31 MR spectroscopy at 1.5. Radiology 169, 615-620 (1988).
30. Glaholm J., Leach M. O., Collins D. J., Mansi J., Sharp J. C., Madden A., Smith I. E. and McCready V. R. In-vivo 31P magnetic resonance spectroscopy for monitoring tumour response in breast cancer. Lancet 1(8650), 1326-1327 (1989).
31. Smith T. A., Glaholm J., Leach M. O., Machin L., Collins D. J., Payne G. S. and McCready V. R. A comparison of in vivo and in vitro 31P NMR spectra from human breast tumours, variations in phosphohpid metabolism. Br. J. Cancer 63, 514-516 (1991).
32. Smith T. A., Glaholm J., Leach M. O., Machin L. and McCready V. R The effect of intra-tumour heterogeneity on the distribution of phosphorus-containing metabolites within human breast tumours: an in vitro study using 31P NMR spectroscopy. NMR. Biomed. 4, 262-267 (1991).
33. Ting Y. -L. T., Sherr D. and Degani H. Variations in the energy and phosphlipid metabolism in normal and cancer human mammary epethelial cells. Anticancer Res. 16, 1381-1388 (1996).
34. Ng T. C., Grundfest S., Vijayakumar S., Baldwin N. J., Majors A. W., Karalis I., Meaney T. F., Shin K. H., Thomas F. J. and Tubbs R. Therapeutic response of breast carcinoma monitored by 31P MRS in situ. Magn. Reson. Med. 10, 125-134 (1989).
35. Arulmozhi V., Narayanan S., Krishnan B., Rao A. S., Veliath A. J. and Ratnakar C. Proton magnetic relaxation studies in normal and cancerous breast tissues. Physiol. Chem. Phys. Med. NMR. 20, 337-343 (1988).
36. Gribbestad I. S., Petersen S. B., Fjosne H. E., Kvinnsland S. and Krane J. 1H NMR spectroscopic characterization of perchloric acid extracts from breast carcinomas and non-involved breast tissue. NMR. Biomed. 7, 181-194 (1994).
37. Gribbestad I. S., Fjosne H. E., Haugen O. A., Nilsen G., Krane J., Petersen S. B. and Kvinnsland S. In vitro proton NMR spectroscopy of extracts from human breast tumours and noninvolved breast tissue. Anticancer Res. 13, 1973-1980 (1993).
38. Speckter H., Blumich B., Just M., Tromel U, Mitze M. and Thelen M. [In vitro NMR spectroscopy of healthy, pathologically changed and carcinomatousbreast tissue samples correlated with histological findings] Rofo. Fortschr. Geb. Rontgenstr. Neuen. Bildgeb. Verfahr. 161, 147-153 (1994).
39. Le Moyec L., Tatoud R., Eugene M., Gauville C., Primot I., Charlemagne D. and Calvo F. Cell and membrane lipid analysis by proton magnetic resonance spectroscopy in five breast cancer cell lines. Br. J. Cancer 66, 623-628 (1992).
40. Adams D. A., DeNardo G. L., DeNardo S. J., Conboy C. B. and Bradbury E. M. 31P surface-coil NMR analysis of metabolic status in KHJJ tumors. Magn. Reson. Med. 2, 419-427 (1985).
41. Wood P. J., Stratford I. J., Sansom J. M., Cattanach B. M., Quinney R. M. and Adams G. E. The response of spontaneous and transplantable murine tumors to vasoactive agents measured by 31P magnetic resonance spectroscopy. International Journal of Radiation Oncol. Biol. Physics 22, 473-476 (1992).
42. Sijens P. E., Bovee W. M. M. J., Seijkens D., Koole P., Los G. and Van Rijssel R. H. Murine mammary tumor response to hyperthermia and radiotherapy. Cancer Res. 47, 6467-6473 (1987).
43. Eskey C. J., Koretsky A. P., Domach M. M. and Jain R. K. Role of oxygen vs. glucose in energy metabolism in a mammary carcinoma perfused ex vivo: Direct measurement by 31P NMR. Proc. Natl Acad. Sci. USA 90, 2646-2650 (1993).
44. Redmond O. M., Stack J. P., O'Connor N. G., Carney D. N., Dervan P. A., Hurson B. J. and Ennis J. T. 31P MRS as an early prognostic indicator of patient response to chemotherapy. Magn. Reson. Med. 25, 30-44 (1992).
45. Merchant T. E., Alfieri A. A., Glonek T. and Koutcher J. A. Comparison of relative changes in phosphatic metabolites and phospholipids after irradiation. Radiat. Res. 142, 29-38 (1995).
46. Mahmood U., Alfieri A. A , Thaler H., Cowburn D. and Koutcher J. A. Radiation dose-dependent changes in tumor metabolism measured by 31P nuclear magnetic resonance spectroscopy. Cancer Res. 54, 4885-4891 (1994).
47. 31P NMR spectroscopy. NMR Biomed. 8, 149-158 (1995).
48. Neeman M., Eldar H., Rushkin E. and Degani H. Chemotherapy-induced changes in the energetics of human breast cancer cells; 31P- and 13C-NMR studies. Biochim. Biophys. Acta 1052, 255-263 (1990).
49. Smith T. A. D., Eccles S., Ormerod M. G., Tombs A. J., Titley J. C. and Leach M. O. The phosphocholine and glycerophosphocholine content of an oestrogen-sensitive rat mammary tumour correlates strongly with growth rate. Br. J. Cancer 64, 821-826 (1991).
50. Smith T. A., Baluch S., Titley J. C., Ormerod M. G., Eccles S., Tombs A. J., Leach M. O., Griffiths J. R. and McCready V. R. The effect of oestrogen ablation on the phospholipid metabolite content of primary and transplanted rat mammary tumours. NMR. Biomed. 6, 209-214 (1993).
51. Daly P. F., Lyon R. C., Faustino P. J. and Cohen J. S. Phospholipid metabolism in cancer cells monitored by 31P NMR spectroscopy. J. Biol. Chem. 262, 14875-14878 (1987).
52. Warden C. H. and Friedkin M. Regulation of phosphatidylcholine biosynthesis by mitogenic growth factors. Biochem. Biophys. Acta 792, 270-280 (1984).
53. Ko K. W., Cook H. W. and Vance D. E. Reduction of phosphatidylcholine turnover in a Nb 2 lymphoma cell line after prolactin treatment. A novel mechanism for control of phosphatidylcholine levels in cells. J. Biol. Chem. 261, 7846-7852 (1986).
54. Ronen S. M., Rushkin E. and Degani H. Lipid metabolism in large T47D human breast cancer spheroids: 31P- and 13C-NMR studies of choline and ethanolamine uptake. Biochim. Biophys. Acta 1138, 203-212 (1992).
55. Ronen S. M., Stier A. and Degani H. NMR studies of the lipid metabolism of T47D human breast cancer spheroids. FEBS Lett. 266, 147-149 (1990).
56. Lowry M., Porter D. A., Twelves C. J., Heasley P. E., Smith M. A. and Richards M A. Visibility of phospholipids in 31P NMR spectra of human breast tumours in vivo. NMR. Biomed. 5, 37-42 (1992).
57. Merchant T. E., Characiejus D., Kasimos J. N., Den Otter W., Gierke L. W. and Glonek T. Phosphodiesters in saponified extracts of human breast and colon tumors using 31P magnetic resonance spectroscopy. Magn. Reson. Med. 26, 132-140 (1992).
58. Merchant T. E., Meneses P., Gierke L. W., Den Otter W. and Glonek T. 31P magnetic resonance phospholipid profiles of neoplastic human breast tissues. Br. J. Cancer 63, 693-698 (1991).
59. McGuire W. L. and De LaGarza M. Improved sensitivity in the measurement of estrogen receptor in human breast cancer. J. Clin. Endocrinol Metab. 37, 986-989 (1973).
60. 13C nuclear magnetic resonance spectroscopy studies. Mol. Pharmacol. 40, 1029-1035 (1991).
61. Furman E., Rushkin E., Margalit R., Bendel P. and Degani H. Tamoxifen induced changes in MCF7 human breast cancer: in vitro and in vivo studies using nuclear magnetic resonance spectroscopy and imagina. J. Steroid Biochem. Mol. Biol. 43, 189-195 (1992).
62. Neeman M. and Degani H. Early estrogen-induced metabolic changes and their inhibition by actinomycin D and cycloheximide in human breast cancer cells: 31P and 13C NMR studies. Proc. Natl Acad. Sci. USA 86, 5585-5589 (1989).
63. Neeman M. and Degani H. Metabolic studies of estrogen- and tamoxifen-treated human breast cancer cells bynuclear magnetic resonance spectroscopy. Cancer Res. 49, 589-594 (1989).
64. 31P nuclear magnetic resonance spectroscopy studies of the response of rat mammary tumours to endocrine therapy. Cancer Res. 48, 89-93 (1988).
65. Baluch S., Midwood C. J., Griffiths J. R , Stubbs M. and Coombes R. C. Monitoring therapeutic response to tamoxifen in NMU-induced rat mammary tumours. Br. J. Cancer 63, 901-904 (1991).
66. Furman E., Margalit R., Bendel P., Horowitz A. and Degani H. In vivo studies by magnetic resonance imaging and spectroscopy of the response to tamoxifen of MCF7 human breast cancer implanted in nude mice. Cancer Commun. 3, 287-297 (1991).
67. Degani H., Furman E. and Fields S. Magnetic resonance imaging and spectroscopy of MCF7 human breast cancer: Pathophysiology and monitoring of treatment. Clinica Chimica Acta 228, 19-33 (1994).
68. Haran E. F., Maretzek A. F., Goldberg I., Horowitz A. and Degani H. Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res. 54, 5511-5514 (1994).
69. Thulborn K. R. and Ackermann J. J. H. Absolute molar concentrations by NMR in inhomogeneous B1. A scheme for analysis of in vivo metabolites. J. Magn. Reson. 55 357-371 (1983).
70. Ordidge R. J., Connolly A. and Lohman J. A. Image-selected in vivo spectroscopy (ISIS). A new technique for spatially-selective NMR spectroscopy. J. Magn. Reson. 66, 283-294 (1986).
71. Sharp J. C. Localized phosphorus NMR spectroscopy of tumours in vivo. University of London, PhD Thesis (1989).
72. Sharp J. C and Leach M. O. Conformal NMR spectroscopy: accurate localization to non-cuboidal volumes with optimum SNR. Magn. Reson. Med. 11, 376-385 (1989).
73. Sharp J. C., Leach M. O and Collins D. J. A single-shot shimming sequence using low-power RF noise pulses for localized in vivo NMR spectroscopy. Phys. Med. Biol. 37, 281-287 (1992).
74. Madden A., Leach M. O., Collins D. J. and Payne G. S. The water resonance as an alternative pH reference: relevance to in vivo 31P NMR localized spectroscopy studies. Magn. Reson. Med. 19, 416-421 (1991).
75. Doyle V. L., Buil M., Payne G. S. and Leach M. O. Calculation of sensitivity correction factors for surface coil MRS. Magn. Reson. Med. 33, 108-112 (1995).
76. Doyle V. L., Payne G. S., Collins D. J., Verrill M. W. and Leach M. O. Quantification of phosphorus metabolites in human calf muscle and soft-tissue tumours from localized MR spectra acquired using surface coils. Phys. Med. Biol. 42, 691-706 (1997).
77. Leach M. O. Introduction to in vivo MRS of cancer: new perspectives and open problems. Anticancer Res. 16, 1503-1514 (1996).
78. Sijens P. E., Eggermont A. M., van Dijk P. V. and Oudkerk M. 31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF-alpha + melphalan isolated limb perfusion. NMR. Biomed. 8, 215-224 (1995).
79. Griffiths J. R. Are cancer cells acidic ? Br. J. Cancer 64, 425-427 (1991).
80. Podo F. and de Certaines J. D. Magnetic resonance spectroscopy in cancer: phospholipid, neutral lipid and lipoprotein metabolism and function. Anticancer Res. 16, 1305-1315 (1996).
81. Dixon R. M. Phosphatidylethanolamine synthesis in the normal and lymphomatous mouse liver; a 13C NMR study. Anticancer Res. 16, 1351-1356 (1996).
82. Negendank W., Li C. W., Padavic Shaller K., Murphy Boesch J. and Brown T. R. Phospholipid metabolites in 1H-decoupled 31P MRS in vivo in human cancer: implications for experimental models and clinical studies. Anticancer Res. 16, 1539-1544 (1996).
83. Pelech S. L. and Vance D. E. Signal transduction via phosphatidylcholine cycles. Trends Biochem. Sci. 14, 28-30 (1989).
84. Billah M. M. and Anthes J. C. The regulation and cellular functions of phosphatidylcholine hydrolysis. Biochem. J. 269, 281-291 (1990).
85. Besterman J. M., Duronio V. and Cuatrecasas P. Rapid formation of diacylglycerol from phosphatidylcholine: a pathway for generation of a second messenger. Proc. Natl Acad. Sci. USA. 83, 6785-6789 (1986).
86. Guy G. R. and Murray A. W. Tumor promoter stimulation of phosphatidylcholine turnover in HeLa cells. Cancer Res. 42, 1980-1985 (1982).
87. Martinson E. A., Goldstein D. and Brown J. H. Muscarinic receptor activation of phosphatidylcholine hydrolysis. Relationship to phosphoinositide hydrolysis and diacylelycerol metabolism. J. Biol. Chem. 264, 14748-14754 (1989).
88. Warden C. H. and Friedkin M. Regulation of phosphatidylcholine biosynthesis by mitogenic growth factors. Biochim. Biophys. Acta 792, 270-280 (1984).
89. Ellis I. O. Practical application of determinants of cell behaviour. Br. Med. Bull. 47, 324-342 (1991).
90. Zeisel S. H. Choline phospholipids - signal transduction and carcinogenesis. Faseb J. 7, 551-557 (1993).
91. Lacal J. C., Moscat J. and Aaronson S. A. Novel source of 1,2-diacylglycerol elevated in cells transformed by Ha-ras oncogene. Nature 330, 269-272 (1987).
92. Moscat J., Cornet M. E., Diaz Meco M. T., Larrodera P., Lopez Alanon D. and Lopez Barahona M. Activation of phosphatidylcholine-specific phospholipase C in cell growth and oncogene transformation. Biochem. Soc. Trans. 17, 988-991 (1989).
93. Katz Brull R. and Degani H. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res. 16, 1375-1380 (1996).
94. Vaupel P. W., Frinak S. and Bicher H. I. Heterogenous oxygen partial pressure and pH distribution in C3H mouse mammary adenocarcinoma. Cancer Res. 41, 2008-2013 (1981).
95. Warburg O. The Metabolism of Tumours. Constable, London (1930).
96. 31P MRS as a method of measuring pH in rat tumours. NMR Biomed. 5, 351-359 (1992).
97. Evelhoch J. L. The pH of human tumours: facts and problems. Radiat. Res. 2, 778-783 (1992).
98. Degani H., Ronen S. M. and Furman-Haran E. Breast cancer: spectroscopy and imaging of cells and tumours. In NMR in Physiology and Biomedicine, ed. by R.J. Gillies. Academic Press, London (1994).
99. Bhujwalla Z. M., Shungu D. C., He Q., Wehrle J. P. and Glickson J. D. MR studies of tumours: relationship between blood flow, metabolism and physiology. In NMR in physiology and biomedicine, ed. by R.J. Gillies. Academic Press, London (1994).
100. Steen R. G., Tamargo R. J., McGover K. A., Rjan S. S., Wehrle J. P. and Glickson J. D. In vivo 31P NMR spectroscopy of subcutaneous 9L gliosarcoma: effects of growth with 1,3bis(2-chloroethyl) 1-notrosourea on tumour bioenergetics and histology. Cancer Res. 48, 676-681 (1988).
101. Oberhaensli R. D., Hilton-Jones D., Bore P. J., Hands L. J., Rampling R. P. and Radda G. K. Biochemical investigation of human tumours in vivo with phosphoras-31 magnetic resonance spectroscopy. Lancet 2(8497), 8-11 (1986).
102. Redmond O. M., Stack J. P., O'Connor N. G., Codd M. B. and Ennis J. T. In vivo phosphorus-31 magnetic resonance spectroscopy of normal and pathological breast tissues. Br. J. Radiol. 64, 210-216 (1991).
103. Merchant T. E., Thelissen G. R., De Graaf P. W., Den Otter W. and Glonek T. Clinical magnetic resonance spectroscopy of human breast disease. Invest. Radiol. 26, 1053-1059 (1991).
104. Hoult D. I. Rotating frame zeumatography. J. Magn. Reson. 33, 183-197 (1979).
105. 31P rotating frame NMR. Proc. Natl Acad. Sci. USA 84, 4283-4287 (1987).
106. Su B., Kappler F., Szwergold B. S. and Brown T. R. Identification of a putative tumor marker in breast and colon cancer. Cancer Res. 53, 1751-1754 (1993).